Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P
Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Germany.
J Intern Med. 1998 Jan;243(1):73-7. doi: 10.1046/j.1365-2796.1998.00252.x.
We report one patient who presented with a spontaneous bleeding complication under phenprocoumon therapy. Oral anticoagulation was initiated due to deep-vein thrombosis which was attributed to an antiphospholipid antibody syndrome. Coagulation analysis revealed a strong and selective reduction of factor IX (F IX) activity to 1%, whereas the other vitamin K-dependent factors (II, VII, X), the prothrombin time and International Normalized Ratio (INR) were within the therapeutic range. After withdrawal of phenprocoumon, all vitamin K-dependent factors including F IX normalized. Because the patient suffered from a recurrence of thrombotic events, he was re-exposed to phenprocoumon and the disproportionate decline of F IX was observed again. These findings indicate an increased sensitivity of F IX to vitamin K antagonists, representing an uncommon mechanism associated with bleeding complications under oral anticoagulant treatment.
我们报告了1例在苯丙香豆素治疗期间出现自发性出血并发症的患者。因抗磷脂抗体综合征导致的深静脉血栓形成而开始口服抗凝治疗。凝血分析显示,因子IX(F IX)活性强烈且选择性地降至1%,而其他维生素K依赖因子(II、VII、X)、凝血酶原时间和国际标准化比值(INR)均在治疗范围内。停用苯丙香豆素后,包括F IX在内的所有维生素K依赖因子均恢复正常。由于该患者出现血栓事件复发,再次接受苯丙香豆素治疗,F IX再次出现不成比例的下降。这些发现表明F IX对维生素K拮抗剂的敏感性增加,这是口服抗凝治疗中与出血并发症相关的一种罕见机制。